Other languages NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
3.93 ^USD	+2.34%		+6.79%	+6.31%

May. 08	Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target	MT
Apr. 17	Sector Update: Health Care Stocks Mixed Wednesday Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity	Apr. 17
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	Apr. 01
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down	Mar. 13
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	Mar. 13
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief	Mar. 04
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	Feb. 29
US Equity Markets Close Higher Thursday Following Jobless Claims Data	Feb. 01
Sector Update: Health Care Stocks Rise in Late Afternoon	Feb. 01
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	Feb. 01
Top Midday Gainers	Feb. 01
NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar	Feb. 01
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment	Feb. 01
Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash	Jan. 18
NeuroBo Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Price Rule	Jan. 09
NeuroBo Pharmaceuticals Submits New Drug Application to FDA for Phase 1 Trial of DA-1726 for Obesity; Shares Rise	Dec. 28
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity	Dec. 28
Top Premarket Gainers	Dec. 13
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee	Nov. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Other languages

Filters